Cargando…

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer

SIMPLE SUMMARY: Therapies with monoclonal antibodies (mAbs) targeting tumor-associated antigens (TAAs) or immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. Nevertheless, the inevitable development of resistance and the failure to respond are among this approach’s disadvantage...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobias, Joshua, Drinić, Mirjana, Schmid, Anna, Hladik, Anastasiya, Watzenböck, Martin L., Battin, Claire, Garner-Spitzer, Erika, Steinberger, Peter, Kundi, Michael, Knapp, Sylvia, Zielinski, Christoph C., Wiedermann, Ursula
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688220/ https://www.ncbi.nlm.nih.gov/pubmed/36428769 http://dx.doi.org/10.3390/cancers14225678

Ejemplares similares

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors
por: Tobias, Joshua, et al.
Publicado: (2020)

Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide
por: Tobias, Joshua, et al.
Publicado: (2017)

Development of the B cell cancer vaccine HER-vaxx for the treatment of her-2 expressing cancers
por: Ede, Nicholas J., et al.
Publicado: (2022)

Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy
por: Wagner, Angelika, et al.
Publicado: (2016)

Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules
por: Wagner, Angelika, et al.
Publicado: (2018)

HER 2/neu protein expression in colorectal cancer
por: Schuell, B, et al.
Publicado: (2006)

Primary vaccine failure to routine vaccines: Why and what to do?
por: Wiedermann, Ursula, et al.
Publicado: (2016)

NKG2A‐checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA‐E
por: Battin, Claire, et al.
Publicado: (2022)

Emerging targets for anticancer vaccination: PD-1
por: Tobias, J., et al.
Publicado: (2021)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Breast Cancer and Her-2/Neu
por: Sherwood, Roy
Publicado: (2005)

A Biomimetic, Silaffin R5-Based Antigen Delivery Platform
por: Reichinger, Daniela, et al.
Publicado: (2022)

Preexisting anti-PF4 antibodies are not further triggered upon vaccination with SARS-CoV-2 vector vaccines in a cohort of 400 health care workers
por: Angelika, Wagner, et al.
Publicado: (2022)

HER-2/neu diagnostics in breast cancer
por: Carney, Walter P, et al.
Publicado: (2007)

The Clinical Importance of the Heterogeneity of HER2 neu
por: Davila, Enrique, et al.
Publicado: (2010)

Obesity and Sex Affect the Immune Responses to Tick-Borne Encephalitis Booster Vaccination
por: Garner-Spitzer, Erika, et al.
Publicado: (2020)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Lack of seroprotection against diphtheria in the Austrian population, in light of reported diphtheria cases in Europe, 2022
por: Wagner, Angelika, et al.
Publicado: (2023)

Machine Learning-Empowered FTIR Spectroscopy Serum Analysis Stratifies Healthy, Allergic, and SIT-Treated Mice and Humans
por: Korb, Elke, et al.
Publicado: (2020)

HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
por: Moelans, Cathy B., et al.
Publicado: (2010)

Anti-HER2/Neu passive-aggressive immunotherapy
por: Mortenson, Eric D, et al.
Publicado: (2014)

HER2/neu testing in primary colorectal carcinoma
por: Ingold Heppner, B, et al.
Publicado: (2014)

Review of the Role of HER2/neu in Colorectal Carcinomas
por: Achalla, Lakshmi Sai Vijay, et al.
Publicado: (2022)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

Reduction of Allergic Lung Disease by Mucosal Application of Toxoplasma gondii-Derived Molecules: Possible Role of Carbohydrates
por: Korb, Elke, et al.
Publicado: (2021)

Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8(+) T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice
por: Chen, Y, et al.
Publicado: (2011)

Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review
por: Kandula, Mahesh, et al.
Publicado: (2013)

Toxoplasma gondii tachyzoite-extract acts as a potent immunomodulator against allergic sensitization and airway inflammation
por: Drinić, Mirjana, et al.
Publicado: (2017)

HER-2/neu oncogene: what does amplification mean?
por: Pavy, J. J., et al.
Publicado: (1993)

Serological Her2/neu-determination in patients receiving Herceptin(®)
por: Thomas, A, et al.
Publicado: (2001)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Expression of HER-2/neu in Oral Squamous Cell Carcinoma
por: Mirza, Sana, et al.
Publicado: (2020)

Expression of Septin 2 and Her2/neu in Colorectal Cancer
por: Hanbuli, Hala M. El, et al.
Publicado: (2021)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Booster immunizations with DNA plasmids encoding HER-2/neu prevent spontaneous mammary cancer in HER-2/neu transgenic mice over life span
por: Provinciali, Mauro, et al.
Publicado: (2017)

Reproducibility of Her2/neu scoring in gastric cancer and assessment of the 10% cut-off rule
por: Behrens, Hans-Michael, et al.
Publicado: (2015)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Freund's vaccine adjuvant promotes Her2/Neu breast cancer
por: Cotroneo, Michelle S, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_as6mp4n1j2g03sj9bep6cr7o32